In the fall of 2023, obstetricians across Dallas watched a new maternal RSV vaccine arrive with real promise: a chance to shield newborns from a virus that hospitalizes thousands of infants each year and kills between 100 and 300 children under five. The timing seemed providential. Health experts recommended vaccinating pregnant women between 32 and 36 weeks of gestation so protective antibodies could cross the placenta before birth—a elegant biological transfer that should dramatically reduce severe respiratory infections in the most vulnerable months of life.
Yet as the 2023–2024 RSV season unfolded, vaccination rates in Dallas told a starkly different story. A new study published in Public Health Reports found that access to this potentially life-saving vaccine was heavily shaped by insurance status and race. Women with private health insurance received the vaccine at rates nearly 19 times higher than those with public insurance: 37% compared to just 2%. Among uninsured women, the rate climbed only slightly to 12%.
The disparities ran even deeper along racial lines. Non-Hispanic white women were vaccinated at a 39% rate, while non-Hispanic Black women received the vaccine at only 6%—a gap rooted not in hesitancy but in the structural inequalities that determine who can access care. Hispanic women in Dallas were vaccinated at 15%, compared to 35% for non-Hispanic Asian women. These numbers reflect a sobering reality: many Black and Hispanic women in Dallas either had no health insurance or relied on public coverage, creating what a Dallas nurse practitioner called "cost-related barriers to accessing and paying for the maternal RSV vaccine."
The barriers were not just financial. A Dallas obstetrician acknowledged the challenge directly: "We aim to prioritize offering the maternal RSV vaccine to all eligible pregnant patients. However, accessibility is an issue. First, there is a national shortage. Second, patients on public insurance can only be vaccinated at federally reimbursed locations." That second constraint meant pregnant women on Medicaid faced geographic and logistical hurdles that private patients did not, even though RSV poses the greatest threat to infants born into under-resourced communities where multiple babies often share cramped spaces.
The research team also identified other factors linked to lower vaccination rates: maternal age under 30, history of smoking or substance exposure, and having multiple previous pregnancies. Yet the most striking finding remained the insurance divide, which illustrated how economic inequality and health inequity are woven together in American medicine.
What made this pattern particularly troubling was that the vaccine appeared to work. Infants born to vaccinated mothers showed measurably reduced rates of severe RSV illness and hospitalization during peak season—exactly what the public health system needed. But that protection, it turned out, would flow disproportionately to families who could already afford private insurance while bypassing many of the mothers whose infants faced the highest risk.
As Dallas moves forward, the study's authors point to a critical juncture: the vaccine's arrival created an opportunity to protect newborns, but realizing that potential requires dismantling the insurance and access barriers that currently determine who benefits. Without urgent action to expand availability at public health clinics and eliminate cost obstacles, this innovation risks becoming another advance that works in theory while leaving the most vulnerable families behind.